Dr. Raghav on Sequencing Therapies for Resectable Versus Unresectable CRC

January 26, 2021
Kanwal Raghav, MBBS, MD

Kanwal Raghav, MBBS, MD, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer.

Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer (CRC).

Sequencing treatment options for patients with CRC has become complicated, as both physical and molecular factors need to be accounted for, especially with regard to metastatic disease, says Raghav. One of the factors that needs to be taken into consideration is the possibility of surgical resection, Raghav explains.

For example, patients with resectable disease can be approached with curative intent, while patients with unresectable disease will primarily be given palliative therapies, Raghav concludes.


x